A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Pearl Therapeutics
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 29 Dec 2017.
- 27 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 29 Dec 2017.
- 27 Jul 2017 Status changed from recruiting to active, no longer recruiting.